Genmab

	22/9 09:29 af E L	it seems I was correct that a decision on Camidanlumab had to be taken this summer:
	22/9 09:16 af E L	Blood Advances: Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma (link)
	22/9 08:23 af Mogan	God morgen :-)
	22/9 08:16 af Helge Larsen/PI-redaktør	Great. Thanks E L. :-)
	22/9 08:04 af E L	Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler Piper Sandler analyst Joseph Catanzaro maintained a Neutral rating and $172 price target on SGen following the company's data from tisotumab's Phase II study in previously treated recurrent/metastatic cervical cancer at ESMO, which the analyst noted were "consistent with June's topline release." Catanzaro believes this data sets the company up for an "accelerated approval path in this setting for tisotumab."
	22/9 08:01 af E L	Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS (link)
	22/9 07:57 af E L	same guy at youtube (link)
	22/9 07:02 af bibob	Tisotumab på ESMO. (link)
	22/9 06:58 af bibob	God morgen. :-)
	22/9 06:21 af transalp	Go morgen.. :)
	22/9 06:10 af Helge Larsen/PI-redaktør	God morgen. :-)
	21/9 23:51 af Sukkeralf	(link)
	21/9 19:18 af peter12	On the latest fireside session JvdW said that Europe would require larger trials for TV
	21/9 19:11 af GeorgeBest	Yes, Japan is very important, they don‘t give their teenage girls the hpv vaccine
	21/9 19:08 af Solsen	Many i Japan...
	21/9 18:49 af E L	maybe it was in the annual report
	21/9 18:48 af E L	the real drama is offcourse in developing countries. a few hundred thousand....
	21/9 18:47 af E L	and Europe is a multiple of that, i think 3 or 4 times as much. we had an article here about it , but can't remember where
	21/9 18:27 af Solsen	(link) Annonce på Twitter siger 13.800+ nye cervical patienter i US årligt. Så stort marked og de har vel også åbnet for at tiso kunne blive blockbuster. Vi har vel heller ikke set weekly behandling, som forventes med bedre resultat.
	21/9 17:19 af GeorgeBest	.@rcoledude presents results from the InnovaTV trial of tisotumab vedotin. There was a 24% response rate in patients w/ recurrent #cervical cancer, >50% of patients had stable disease beyond 6 months! (link)
	21/9 17:18 af bikube	Det eneste jeg har, der ikke er rødt i dag er mine Bear Tesla.
	21/9 17:14 af Bulder	Det her er kun begyndelsen på tiso. Der er større forventninger til andre kræftformer. F,eks, bugspytkirtlen, hvor præklinikken så god ud. Desuden vil der komme kombinationsbehandlinger.
	21/9 17:14 af Helge Larsen/PI-redaktør	Novo også drønstærk i dag.
	21/9 17:04 af Mcjean	Yep! Tak til Genmab for at give folk håb.

	21/9 17:01 af Solsen	Imponerende ganske enkelt !
	21/9 17:00 af GeorgeBest	-0,16% er til at holde til på en dag hvor DAX futter er neden med 4,5%
	21/9 16:53 af Don Joning	Det giver jo alt sammen til at lave en robust forretning, med mange ben at stå på og det er jo ikke det nemmeste i verden de udvikler på - det kunne også have været et hard stop uden signifikant effekt og 0 værdi i det område.
	21/9 16:50 af E L	fiercebiotech - ESMO: Seattle Genetics' ADC candidate curbs hard-to-treat cervical cancer - (link)
	21/9 16:47 af GeorgeBest	men tiso kan måske også bruges i andre cancer former. der skulle også komme data på det i år
	21/9 16:46 af GeorgeBest	jo
	21/9 16:46 af Don Joning	ja, men er det ikke 50/50
	21/9 16:46 af GeorgeBest	skal også deles med SGEN
	21/9 16:45 af Don Joning	tak GB det er da alligevel også lidt...
	21/9 16:45 af GeorgeBest	årligt topsalg
	21/9 16:45 af GeorgeBest	Tiso: jeg har set estimater på et topsalg på 750M USD i cervical cancer
	21/9 16:44 af GeorgeBest	knock your socks off data er mere relateret til epcoritamab og PD-L1x4-1BB
	21/9 16:44 af Don Joning	nogen der har nogen bud på hvor værdifuldt tiso i cervical cancer kan blive?
	21/9 16:43 af bikube	Det er da det man forstår ved "late breaking".
	21/9 16:43 af GeorgeBest	der var ikke forventet mere for tiso
	21/9 16:41 af Macabo	ORR 24% og DOR 8,3 måneder - det er godt men ikke knock of socks niveau
	21/9 16:35 af GeorgeBest	thanks E L
	21/9 16:34 af E L	correction for the link GB (link)
	21/9 16:31 af GeorgeBest	The results of the tisotumab vedotin phase 2 clinical trial are encouraging as they demonstrate clinically meaningful, durable responses with a manageable side effect profile
	21/9 16:29 af GeorgeBest	(link)
	21/9 16:28 af GeorgeBest	Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
	21/9 14:55 af E L	(link) Amgen showing bispecific CD3x PSMA , like JNJ-63898081
	21/9 11:14 af Bulder	Could be RA. Has been discussed before. I think Janssen has an unused IND for dara in RA. (link)
	21/9 10:19 af E L	ok. we know Mayo has a Dara trial in CLL, in combination with Ibrutinib, will be interesting to see
	21/9 09:55 af Darvin	EL It was Rajkumar who announced It yesterday. And - depending on how you read the text - I read it as if they will open a trial for various autoimmune diseases - but only my way to read it
	21/9 09:50 af Darvin	Tillykke og godt gået Helge :-D